An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease

Trial Profile

An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 May 2016

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2016 Results published in the British Journal of Clinical Pharmacology
    • 30 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top